• Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Science
    • Quatramer
    • TridentAI
  • Investors
  • Contact Us
Hillstream
  • Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Science
    • Quatramer
    • TridentAI
  • Investors
  • Contact Us
    Loading posts...

  • February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers

    Please join us on R & D Day 8:00 AM - Targeting Ferroptosis to Iron Out Resistant Cancers
    February 22, 2022
    Announcement

Recent Posts

  • Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
  • Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
  • February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers
  • Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma
  • Hillstream BioPharma Provides Business Review with Key Pipeline Updates

Address:

245 Main St., Ste. 204
Chester, NJ

Tel: +1 (917) 214-3514
Mail: info@hillstreambio.com
Hillstream Biopharma

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807

Tel: 1-908-955-3140
Mail: info@hillstreambio.com

Latest News

  • Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022 May 6, 2022
  • Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers March 2, 2022
  • February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers February 22, 2022

© Copyright 2022. Hillstream Biopharma, Inc. All Rights Reserved